The Underlying Value of Biotech IPOs
While Covid-19 has brought hospitality and other service sectors to a standstill, the biopharmaceutical IPO market is booming. Royalty Pharma, a company focused on buying biopharmaceutical royalties from drug developers, went public on June 16, 2020 at a value of $2.18 billion. Royalty Pharma’s IPO is the second-largest biopharmaceutical…
